PharmaDeals Review Business Commentaries
Dr Fintan Walton, PharmaVentures’ CEO, provides monthly comment on topical biotechnology and pharmaceutical industry issues. Includes access to Fintan’s commentaries broadcast on PharmaTelevision.
Available as PDF
(Subscribers only)
Therapy Focus: Wound Care
From issue 76 of the PharmaDeals Review (2006-10-01)
The niche market of wound care is occupied by a group of around 50 speciality biopharmaceutical companies with proprietary technologies focusing on a number of therapeutic areas. Wound care is a tremendously diverse market - from plasters and bandages to autologous skin replacement - so that within individual approaches there are relatively few competitors. In 40% of cases current standard therapies are ineffective in wound healing, and therefore this article highlights some of the emerging therapies and products being developed to address this unmet clinical need.
Available as PDF
(Subscribers only)
POZEN Forgets Migraines to Collaborate with AstraZeneca
From issue 75 of the PharmaDeals Review (2006-09-01)
The turbulent history and current potential are examined of POZEN, a North Carolina-based pharmaceutical company, whose fortunes took a turn for the positive at the beginning of August 2006 when it turned away from its migraine drugs, unsuccessful to date, to enter into a global collaboration agreement with AstraZeneca. The deal is for fixed-dose combinations, in a single tablet, of the proton pump inhibitor esomeprazole magnesium with the NSAID naproxen sodium. The product is indicated for pain and inflammation associated with osteoarthritis in patients who are at risk of developing NSAID-associated gastric ulcers.
Available as PDF
(Subscribers only)
Medicure Takes Over US Marketing of Aggrastat®
From issue 75 of the PharmaDeals Review (2006-09-01)
Medicure has acquired the US rights to Aggrastat® Injection (tirofiban hydrochloride) from MGI PHARMA. In so doing, it has gained the opportunity to establish a sales and marketing capability in the cardiovascular market ahead of the anticipated launch of its lead pipeline candidate MC-1, a cardioprotective agent that is soon to start Phase III trials. Assuming that MC-1 is able to gain regulatory approval, the deal can be regarded as a positive move for Medicure. For MGI PHARMA, the transaction finally sees it rid itself of a long unwanted product that it acquired along with its US$178 M acquisition of Guilford Pharmaceuticals in June 2005. This article discusses the ramifications of the deal and the motivations of the companies involved.
Available as PDF
(Subscribers only)
Biopharmaceutical Clusters in Europe: Differences and Similarities
From issue 75 of the PharmaDeals Review (2006-09-01)
Data from PharmaDeals® Agreements for the period May 1996 to December 2005 were used to locate European biopharmaceutical companies and analyse any geographic patterns in deal making and therapeutic area. Some 149 regional clusters were identified that are active in deal making. This article focuses, for the most part, on the 23 main clusters and gives an overview of their characteristics, which sheds some light on differences and similarities both between and within regional clusters in terms of their therapeutic focus. By linking the differences in specialisation within clusters to some other cluster characteristics, some interesting types of clusters were found.
Available as PDF
(Subscribers only)
Therapy Focus: Atopic Eczema
From issue 75 of the PharmaDeals Review (2006-09-01)
Atopic eczema, or atopic dermatitis, is a chronic inflammatory skin disease that affects 15-20% of children and 2-10% of adults in industrialised nations. Having a substantial negative impact on quality of life, eczema represents a significant disease burden that has produced a global market worth over US$1 B. Despite this, there have been relatively few new therapies to appear over the past few decades. This article looks at underlying causes of eczema, both genetic and environmental, and discusses the existing treatment regimes as well as novel therapies currently in development.
Last Issue PDF
RSS